New platform for Drug EXTENDED-release intended for the treatment of solid tumors


INTRAGEL is a science-based company engaged in developing an innovative, state-of-the-art treatment for solid tumors based on an intra-tumoral injectable delivery system with extended-release of anticancer drugs.


INTRAGEL’s first product addresses an unmet need for head and neck cancer, which is the sixth most common cancer in Europe, with 250,000 cases per year. The disease afflicts approximately 50,000 people per year in the US and 400,000 per year worldwide.

approximately 50% of these patients cannot receive chemotherapy, the standard of care, for a variety of reasons and therefore, in the majority of cases, inevitably face death. INTRAGEL’s treatment is designated for these cases.  

THE Market

The global Head and Neck Cancer Drugs/Therapeutics market size is expected to gain market growth with a CAGR of 4.0% in the forecast period of 2020 to 2025 and will be expected to reach $1.5B by 2025, from $1.2B million in 2019.

IntraGel’s market is those 50% unfit patients, 350K/yr, translated to a market of $0.7B


 INTRAGEL’s novel technology features a pre-filled syringe that is ready to be injected into the tumor. The syringe contains an anti-cancer drug formulated into a de-novo gel-like, hydrophobic, biocompatible and biodegradable polymer, that slowly releases the drug into the tumor over a few weeks with minimal systemic toxicity.

INTRAGEL’s technology can be applied to a wide range of anti-cancer drugs and is suitable for various types of tumors.

INTRAGEL’s technology is protected by a patent application.

INTRAGEL has so far achieved excellent pre-clinical results.

INTRAGEL’s proprietary technology is protected by a patent application.

INTRAGEL achieved excellent pre-clinical results.



PETER SIMAN - CEO & Co-Founder

Brings vast experience in project management and R&D in a wide range of chemistry-based medical devices.

Holds a B.Sc and M.Sc in chemistry from the Hebrew University, Ph.D. from Ben-Gurion University in Israel and conducted his post-doctorate at the University of California, Berkeley, USA

PROF. AVI DOMB - Co-Founder

As an inventor of a dozen approved products Avi brings vast experience in pharmaceutical development and innovation.

Holds a Ph.D. in chemistry and undergraduate degrees in chemistry, pharmaceutics, and law.

AVNER GEVA -Co-Founder

Brings experience as a seasoned entrepreneur with more than ten years in the Israeli Medtech/Pharma industry.

Previously founded and served as CEO of Vensica Therapeutics, where Avner led large, strategic and successful funding rounds.

Has a background in premedical studies and molecular biology (B.Sc, Yale) and BioMedical Engineering (M.Sc. Technion).


ZOHAR GENDLER -Chairman of the Board

CEO and Managing Partner of NGT3 VC. Led the establishment of and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), Corindus (sold to Siemens Healthcare for $1.1B), and many others.


Holds a Ph.D. in Biochemistry and Microbiology from the Department of Molecular Microbiology and Biotechnology, Tel Aviv University. Spanning a career of over fifteen years, Amir brings extensive experience from the pharmaceutical industry in managing and developing the skills and capabilities of multidisciplinary teams.



Manages the finances of NGT portfolio companies with strong, proven leadership.

Involved in fund-raising, negotiations, and complex transactions.




Head of Sharett Institute of Oncology.

Specialist in ENT, Medical and Radiation Oncology.


Contact us

Dr. Peter Siman

CEO & Co-Founder

Mobile:  +972-53-583-0767

Office:   +972-4-609-8606

Fax:       +972-4-609-8600

Email:     peter@intra-gel.com 

Website: http://www.intra-gel.com


Investors - Contact Us

Entrepreneurs - Contact Us